Suppr超能文献

[慢性心力衰竭的治疗]

[The therapy of chronic heart failure].

作者信息

Trenckmann H

机构信息

Klinik für Innere Medizin, Karl-Marx-Universität, Leipzig.

出版信息

Z Gesamte Inn Med. 1990 Jun 15;45(12):342-7.

PMID:2201131
Abstract

A rational therapy of the chronic cardiac insufficiency should be performed according to a certain scheme, in which case the knowledge of the basic disease is necessary for the causal treatment. Apart from the general measures the medicamentous therapy is of particular significance. Hereby up to now the digitalis glycosides remained the remedy of primary choice. They are without doubt indicated in the latent and manifest cardiac insufficiency, consequently from the transition of the NYHA stage II into stage III, in tachycardiac disturbances of rhythm also without cardiac insufficiency in form of auricular fibrillation and auricular flutter as well as in the paroxysmal supraventricular tachycardia. Prophylactic, preoperative applications of glycosides and such ones which are performed only for reasons of age are not justified. Also a maintenance therapy is in most cases no more necessary after removal of the cause of the cardiac insufficiency. - Diuretics are to be used in an insufficiency which continues existing despite application of glycosides. Their application must be performed as protracted as possible. - The therapies with vasodilators, such as prazosin, hydralazine and nitrates, which were performed during the last years, showed, indeed, initial success, but no long-term effect. Another fact it is, however, with the angiotensin-converting enzyme (ACE) inhibitors captopril and enalapril, which are to be regarded as second grade medicaments in combination with glycosides and diuretics. Whether or not they will supersede the glycosides, is at present still an open question. Other positively inotropic medicaments which in comparison to the glycosides show a larger therapeutic breadth are still being developed.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

慢性心功能不全的合理治疗应按照一定方案进行,在这种情况下,了解基础疾病对于病因治疗是必要的。除一般措施外,药物治疗具有特别重要的意义。迄今为止,洋地黄苷仍是首选药物。毫无疑问,它们适用于潜在和明显的心功能不全,即从纽约心脏病协会(NYHA)II级转变为III级时,也适用于无心力衰竭的快速心律失常,如心房颤动和心房扑动,以及阵发性室上性心动过速。预防性、术前使用洋地黄苷以及仅因年龄原因使用洋地黄苷是不合理的。而且在去除心功能不全的病因后,大多数情况下维持治疗也不再必要。——利尿剂应用于尽管使用洋地黄苷但仍持续存在的心功能不全。其应用必须尽可能持续进行。——过去几年使用的血管扩张剂,如哌唑嗪、肼屈嗪和硝酸盐类药物,确实显示出初步疗效,但没有长期效果。然而,对于血管紧张素转换酶(ACE)抑制剂卡托普利和依那普利,它们与洋地黄苷和利尿剂联合使用时被视为二线药物。它们是否会取代洋地黄苷,目前仍是一个悬而未决的问题。与洋地黄苷相比具有更大治疗范围的其他正性肌力药物仍在研发中。(摘要截取自250字)

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验